반응식
[CH3:1][C:2]1[N:3]=[CH:4][C:5]([NH:8][C:9]2[C:18]3[C:13](=[CH:14][CH:15]=[C:16]([OH:19])[CH:17]=3)[N:12]=[CH:11][N:10]=2)=[N:6][CH:7]=1.C(O[CH:23](OCC)[CH2:24][O:25][C:26]1[CH:27]=[CH:28][C:29](F)=[N:30][CH:31]=1)C.[NH:36]1[CH2:39][CH2:38][CH2:37]1>>[N:36]1([CH2:23][CH2:24][O:25][C:26]2[CH:27]=[CH:28][C:29]([O:19][C:16]3[CH:17]=[C:18]4[C:13](=[CH:14][CH:15]=3)[N:12]=[CH:11][N:10]=[C:9]4[NH:8][C:5]3[CH:4]=[N:3][C:2]([CH3:1])=[CH:7][N:6]=3)=[N:30][CH:31]=2)[CH2:39][CH2:38][CH2:37]1참가 물질
4
실험 절차
Using 4-[(5-methylpyrazin-2-yl)amino]quinazolin-6-ol, 5-(2,2-diethoxyethoxy)-2-fluoropyridine and azetidine, and in the same manner as in Example 31 or according to a method similar to it or according to a combination thereof with an ordinary method, the entitled compound (22 mg) was obtained as a pale yellow solid.
출처 및 근거
- ORD 기록
- ord-aa604c5ac5a14429b7f8b1c3794d61f7
- 출처 데이터셋
- uspto-grants-2014_09
- 특허 번호
- US08846700B2
연결된 노트
불러오는 중…